PortfoliosLab logoPortfoliosLab logo
ISIN
US9186401033
CUSIP
918640103
IPO Date
Aug 9, 2018

Highlights

Market Cap
$2.26M
Total Revenue (TTM)
$601.00K
Gross Profit (TTM)
$574.00K
EBITDA (TTM)
-$18.51M
Year Range
$0.31 - $1.50
Avg. Volume (1M)
514
Avg. Volume Value (1M)
$585.21

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Vaccinex, Inc.

Often compared with VCNX:
VCNX vs. XUU.TOVCNX vs. XEQT.TO

Performance

VCNX Performance Chart

Vaccinex, Inc. (VCNX) is down 21.4% since the beginning of the year. At $1 per share, VCNX is trading 43.6% below its 52-week high of $2. Investors who bought $1,000 worth of VCNX shares 5 years ago would now be looking at an investment worth $2.


Loading charts...

Benchmark

Compare this symbol against anything

Returns By Period

Vaccinex, Inc. (VCNX) has returned -21.37% so far this year and 7.06% over the past 12 months.


Vaccinex, Inc.

1D
-28.33%
1M
-17.09%
6M
-38.27%
YTD
-21.37%
1Y
7.06%
3Y*
-76.04%
5Y*
-72.26%
10Y*
ALL TIME*
-63.32%

Benchmark (S&P 500 Index)

1D
0.70%
1M
0.09%
6M
7.94%
YTD
9.41%
1Y
20.07%
3Y*
17.84%
5Y*
11.25%
10Y*
13.26%
ALL TIME*
8.09%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VCNX Monthly Returns History

Based on dividend-adjusted daily data since Aug 9, 2018, VCNX's average daily return is +0.01%, while the average monthly return is -4.36%.

Historically, 33% of months were positive and 67% were negative. The best month was Jul 2020 with a return of +75.4%, while the worst month was Dec 2024 at -74.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, VCNX closed higher 42% of trading days. The best single day was Oct 20, 2025 with a return of +104.2%, while the worst single day was Dec 17, 2024 at -61.4%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202627.38%-24.82%-1.41%-23.49%28.70%2.00%-17.09%-21.37%
202522.45%-8.33%-30.82%28.78%-5.63%-21.06%12.32%-39.02%24.00%1.79%10.90%53.66%9.74%
2024-5.91%0.50%-15.81%-19.84%14.14%-4.28%-21.42%12.35%-40.66%-17.94%35.48%-74.07%-89.47%
2023-7.68%-16.97%-19.13%-9.89%12.53%-12.12%-18.51%-30.02%-62.89%-14.96%-23.53%-9.54%-93.12%
202245.19%-5.30%-7.69%0.00%-13.64%-5.26%-2.78%-17.41%-42.92%20.00%-15.79%28.85%-38.03%
202114.01%57.63%-19.89%-13.42%-7.75%17.65%-12.50%-2.04%-10.00%-11.57%-16.75%-34.59%-49.76%

Benchmark Metrics

Vaccinex, Inc. has an annualized alpha of -4.64%, beta of 0.58, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 09, 2018.

  • This stock participated in 219.83% of S&P 500 Index downside but only -58.46% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.58 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-4.64%
Beta
0.58
0.01
Upside Capture
-58.46%
Downside Capture
219.83%

Return for Risk

Risk / Return Rank

VCNX ranks 60 for risk / return — above 60% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.


VCNX Risk / Return Rank: 6060
Overall Rank
VCNX Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
VCNX Sortino Ratio Rank: 7979
Sortino Ratio Rank
VCNX Omega Ratio Rank: 8484
Omega Ratio Rank
VCNX Calmar Ratio Rank: 4646
Calmar Ratio Rank
VCNX Martin Ratio Rank: 4545
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

Risk / Return Metrics

The table below present risk-adjusted performance metrics for Vaccinex, Inc. (VCNX) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VCNXBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-1.40

Sortino ratioReturn per unit of downside risk

-0.02

Omega ratioGain probability vs. loss probability

1.31

1.25

+0.05

Calmar ratioReturn relative to maximum drawdown

0.05

2.00

-1.95

Martin ratioReturn relative to average drawdown

0.10

8.49

-8.39

Dividends

Dividend History


Vaccinex, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Vaccinex, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vaccinex, Inc. was 99.99%, occurring on Nov 5, 2025. The portfolio has not yet recovered.

The current Vaccinex, Inc. drawdown is 99.97%.


Drawdown

Fall

Recovery

Underwater

Related event

-99.99%Nov 2025
7y 3mo
7y 12moAug 2018 - now

Drawdown Indicators


VCNXBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-99.99%

-56.78%

-43.21%

Max Drawdown (1Y)

Largest decline over 1 year

-64.95%

-9.10%

-55.85%

Max Drawdown (3Y)

Largest decline over 3 years

-99.41%

-18.90%

-80.51%

Max Drawdown (5Y)

Largest decline over 5 years

-99.94%

-25.43%

-74.51%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-99.97%

-1.58%

-98.39%

Average Drawdown

Average peak-to-trough decline

-83.10%

-10.70%

-72.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

31.36%

2.14%

+29.22%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Vaccinex, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Vaccinex, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with VCNX

Add Vaccinex, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with VCNX